2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

Developed by the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, this guideline serves as an update to “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure” (JNC 7) published in 2003. In June 2013, the National Heart, Lung and Blood Institute (NHLBI) announced it would no longer be involved in developing clinical guidelines. At the time, the Joint National Committee on Prevention, Detection, Evaluation and Treatment of high blood pressure (JNC) was working on the JNC-8 publication and declined partnership with the ACC/AHA. The 2014 JNC-8 was published in December 2013. The major difference between the two guidelines is the 2017 ACC/AHA recommendation to initiate therapy for treatment of HTN in those with CVD or ASCVD risk factors for SBP ≥ 130 and DBP ≥ 80 as compared to a BP of ≥ 140/90 in this same population in the JNC-8 guideline. In those without risk factors the threshold for initiation of treatment is a BP > 140/90 for both the JNC-8 and 2017 ACC/ AHA HTN guidelines.

Download PDF Version